KEYTRUDA (R) (Pembrolizumab) plus KISPLYX (R) (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2021; 44 (1-2): 70

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索